The association of lncRNAs with several subtypes of leukemia, such as MEG3, IRAIN, and UCA1 related to AML and ANRIL, LUNAR1, in ALL, increase the possibility to use them as biomarkers for the diagnosis, prognosis, and treatment (to provide a target) for the different subtypes of this disease. This evidence concerns the gene CDKN2B-AS1 and acute myeloid leukemia.